[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582245":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":38,"responsibleParty":58,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":12,"enrollmentInfo":75,"targetDuration":12,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":41,"whyStopped":12,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of Michigan","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of Care","NO_INTERVENTION","The current standard of care surgical prophylaxis regimen",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Cefoxitin","EXPERIMENTAL","Administration of Cefoxitin 2000 mg within 30 minutes of incision to the existing standard of care intervention",[18],"Drug: Cefoxitin",[20],{"type":21,"name":14,"description":22,"armGroupLabels":23,"otherNames":12},"DRUG","Cefoxitin 2000 mg Bolus Injection",[14],[25],{"name":26,"affiliation":5,"role":27},"Manjunath Pai, PharmD","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":12,"email":33},"Alexsas Matvekas, BS","CONTACT","7346470006","matvekas@umich.edu",{"name":35,"role":31,"phone":36,"phoneExt":12,"email":37},"June Sullivan, MBA","734.615-3488","jusulli@med.umich.edu",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Michigan Medicine","RECRUITING","Ann Arbor","Michigan","48108","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-83.74088,42.27756,{"lat":51,"lon":50},[54],{"name":55,"role":31,"phone":56,"phoneExt":12,"email":57},"Amit Pai","518-429-1476","amitpai@med.umich.edu",{"type":27,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"Manjunath Prakash Pai","Professor",[62],{"name":63,"class":64},"Agency for Healthcare Research and Quality (AHRQ)","FED","100582245","phase-1-precision-antibiotic-dosing-for-appendectomy-100582245",false,"NCT06860802","Precision Antibiotic Dosing for Appendectomy","Aim 3 - Precision Coordination of Therapeutic and Prophylactic Antibiotics to Reduce Infection, Toxicity, and Emergence of Resistance Following Acute Abdominal Surgery","PANDA","Inclusion Criteria:\n\n* Diagnosis of acute appendicitis and plan to undergo appendectomy at the University of Michigan\n\nExclusion Criteria:\n\n* Prisoners\n* Patients that are pregnant\n* Patients with perforation or abscess on CT Scan","ALL","18 Years",{"count":76,"type":77},46,"ESTIMATED","INTERVENTIONAL",[80],"PHASE1","This research is studying a drug called cefoxitin already approved by the Food and Drug Administration (FDA) to reduce the risk of infection after surgery to remove an appendix. Researchers are studying a large group of people to continue to learn how best to dose antibiotics. This research will compare the current standard treatment which is a single dose prior to surgery to a new method that includes adding another dose of cefoxitin within 30 minutes of starting the surgery. This study will measure cefoxitin concentrations in blood, fat, and appendix tissue samples to compare the standard dosing method to our new method. This information will help us figure out the right dose of this drug to prevent infection after surgery to remove an appendix.",[83],"Appendicitis (Diagnosis)",[14,85,86],"Appendectomy","Surgical Site Infections","2026-03-05",{"date":89,"type":90},"2026-03-06","ACTUAL",{"date":92,"type":90},"2025-02-28",{"date":94,"type":77},"2026-09-30",{"name":5,"class":6},1]